JP2010503386A5

JP2010503386A5 -

Download PDF

Info

Publication number: JP2010503386A5
Authority: JP; Japan
Prior art keywords: fragment; antibody; seq; chain; fab
Prior art date: 2007-09-12
Legal status : Granted

Application number

JP2009527737A

Other languages

English (en)

Japanese (ja)

Other versions

JP2010503386A (ja

JP5513114B2 (ja

Filing date

2007-09-12

Publication date

2010-10-14

2006-09-15 Priority claimed from EP06019399A external-priority patent/EP1900752A1/en

2007-09-12 Application filed filed Critical

2010-02-04 Publication of JP2010503386A publication Critical patent/JP2010503386A/ja

2010-10-14 Publication of JP2010503386A5 publication Critical patent/JP2010503386A5/ja

2014-06-04 Application granted granted Critical

2014-06-04 Publication of JP5513114B2 publication Critical patent/JP5513114B2/ja

Status Active legal-status Critical Current

2027-09-12 Anticipated expiration legal-status Critical

Links

239000012634 fragment Substances 0.000 claims description 22
239000003814 drug Substances 0.000 claims description 9
102000010451 Folate receptor alpha Human genes 0.000 claims description 6
102100035139 Folate receptor alpha Human genes 0.000 claims description 6
108050001931 Folate receptor alpha Proteins 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
229940124597 therapeutic agent Drugs 0.000 claims description 6
230000002018 overexpression Effects 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
125000003275 alpha amino acid group Chemical group 0.000 claims 3
150000007523 nucleic acids Chemical class 0.000 claims 3
102000039446 nucleic acids Human genes 0.000 claims 3
108020004707 nucleic acids Proteins 0.000 claims 3
206010033128 Ovarian cancer Diseases 0.000 claims 2
206010061535 Ovarian neoplasm Diseases 0.000 claims 2
229940127089 cytotoxic agent Drugs 0.000 claims 2
239000012636 effector Substances 0.000 claims 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
241000588724 Escherichia coli Species 0.000 claims 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
239000002246 antineoplastic agent Substances 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
239000002254 cytotoxic agent Substances 0.000 claims 1
231100000599 cytotoxic agent Toxicity 0.000 claims 1
239000000539 dimer Substances 0.000 claims 1
239000013604 expression vector Substances 0.000 claims 1
239000003550 marker Substances 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
238000001959 radiotherapy Methods 0.000 claims 1
230000001105 regulatory effect Effects 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
230000002103 transcriptional effect Effects 0.000 claims 1
239000013598 vector Substances 0.000 claims 1
208000035475 disorder Diseases 0.000 description 4
238000000034 method Methods 0.000 description 3
238000011221 initial treatment Methods 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1

JP2009527737A 2006-09-15 2007-09-12 卵巣癌の放射免疫療法のためのヒト抗−葉酸受容体アルファ抗体および抗体フラグメント Active JP5513114B2 (ja)